Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Life Biosciences is raising $99,999,997.00 in new funding. Sources indicate as part of senior management Co-Founder and Chief Investment Officer, Tristan Edwards played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Life Biosciences
Life Biosciences is dedicated to developing novel therapies to extend healthy human lifespan by targeting the biological causes of aging. Founded in 2017 and headquartered in Boston, MA, Life Biosciences is pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop pharmaceutical treatments with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs. Each of our platforms is based on science in-licensed from world-leading researchers. They each have the potential to prevent, treat, and/or reverse multiple aging-related diseases that have critical unmet medical needs. We have exclusive licenses with leading academic institutions underpinned by strong composition of matter and method of use patents.

To learn more about Life Biosciences, visit http://www.lifebiosciences.com/

Contact:
Tristan Edwards, Co-Founder and Chief Investment Officer
857-400-9245
tristan@lifebiosciences.com
https://www.linkedin.com/in/atristanedwards/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved